



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2020/05/22
(87) Date publication PCT/PCT Publication Date: 2020/12/03
(85) Entrée phase nationale/National Entry: 2021/11/11
(86) N° demande PCT/PCT Application No.: US 2020/034146
(87) N° publication PCT/PCT Publication No.: 2020/242913
(30) Priorité/Priority: 2019/05/30 (US16/426,124)

(51) Cl.Int./Int.Cl. *C12N 15/86* (2006.01),
C12Q 1/686 (2018.01), *C12Q 1/6876* (2018.01),
C12Q 1/70 (2006.01)
(71) Demandeur/Applicant:
TRIZELL LTD., GB
(72) Inventeurs/Inventors:
MYKKANNEN, JENNI, FI;
PELTONEN, HANNA, FI;
HASSINEN, MINNA, FI;
YLA-HERTTUALA, SEPPO, FI;
PARKER, NIGEL, GB
(74) Agent: BENOIT & COTE INC.

(54) Titre : DOSAGE DE VECTEUR VIRAL A TRES HAUTE PRECISION
(54) Title: ULTRA-HIGH-PRECISION VIRAL VECTOR ASSAY




FIGURE 1

(57) **Abrégé/Abstract:**

During manufacture of replication-deficient viral gene therapy vector, random mutation or other events may produce undesirable replication-competent virus ("RCV"). Viral gene therapy vector manufacturers thus assay for the presence of contaminating RCV by assaying for serial infection, i.e., transducing target cells with the viral vector, and then lysing the transduced cells, and then mixing the lysate with live assay cells, and then microscopically observing the assay cells to visually determine whether they have been infected with virus. We have tested various alternative approaches, and surprisingly found that droplet digital PCR is not only faster than the prior art approach, but is also over an order of magnitude more sensitive, able to detect, for example, in 3 x 10¹⁰ assay cells, as few as seven (7) replication competent adenoviruses ("RC").

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

03 December 2020 (03.12.2020)



(10) International Publication Number

WO 2020/242913 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) C12Q 1/686 (2018.01)

C12Q 1/6876 (2018.01) C12Q 1/70 (2006.01)

(21) International Application Number:

PCT/US2020/034146

(22) International Filing Date:

22 May 2020 (22.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16/426,124 30 May 2019 (30.05.2019) US

(71) Applicant: **TRIZELL LTD.** [GB/GB]; Sanderum House Oakley Road, Chinnor, Oxfordshire OX39 4TW (GB).(71) Applicant (for US only): **PHARMACEUTICAL PATENT ATTORNEYS** [US/US]; 801 Brickell Avenue, 9th Floor #9101, Miami, FL 33131 (US).(72) Inventors: **MYKKANNEN, Jenni**; Microkatu 1 S, Kuopio, FI-70210 (FI). **PELTONEN, Hanna**; Microkatu 1 S, Kuopio, FI-70210 (FI). **HASSINEN, Minna**; Microkatu 1 S, Kuopio, FI-70210 (FI). **YLA-HERTTUALA, Sep-po**; Microkatu 1 S, Kuopio, FI-70210 (FI). **PARKER, Nigel**; Sanderum House Oakley Road, Chinnor, Oxfordshire OX39 4TW (GB).(74) Agent: **POHL, Mark**; Pharmaceutical Patent Attorneys, LLC, 801 Brickell Avenue, 9th Floor #9101, Miami, FL 33131 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: ULTRA-HIGH-PRECISION VIRAL VECTOR ASSAY




FIGURE 1

(57) **Abstract:** During manufacture of replication-deficient viral gene therapy vector, random mutation or other events may produce undesirable replication-competent virus ("RCV"). Viral gene therapy vector manufacturers thus assay for the presence of contaminating RCV by assaying for serial infection, i.e., transducing target cells with the viral vector, and then lysing the transduced cells, and then mixing the lysate with live assay cells, and then microscopically observing the assay cells to visually determine whether they have been infected with virus. We have tested various alternative approaches, and surprisingly found that droplet digital PCR is not only faster than the prior art approach, but is also over an order of magnitude more sensitive, able to detect, for example, in 3 x 10¹⁰ assay cells, as few as seven (7) replication competent adenoviruses ("RC").

[Continued on next page]

WO 2020/242913 A1



DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

Ultra-High-Precision Viral Vector Assay

Cross-reference to related applications:

This application asserts priority from United States Utility Patent Application Serial No. 16/426124 filed 30 May 2019 and incorporated here by reference.

Statement regarding federally sponsored research or development:

Not applicable

The names of the parties to a joint research agreement:

Not applicable

Reference to a Sequence Listing:

This application includes and incorporates by reference the PatentIn™ file of record in this application.

Statement regarding prior disclosures by the inventor or a joint inventor:

Not applicable

Background:

Certain viral gene therapy vectors are by design unable to replicate in a patient. For example, to replicate in normal human cells, an adenovirus requires functioning E1a, E1b and E3 genome regions. Viral gene therapy vectors may be made replication deficient by deleting or mutating these regions.

Nonetheless, during manufacture of viral gene therapy vector, undesirable replication-competent virus ("RCV") may form due to random mutation or other events. For example, E1a-deleted adenoviral vector may be manufactured in HEK293 cells, which contain a functional E1a region. Spontaneous recombination may theoretically add a functional E1a region back into an adenovirus, create a replication competent adenovirus ("RCA").

Viral gene therapy vector manufacturers thus assay replication-deficient viral vector for the presence of contaminating RCV. Regulatory agencies, *i.e.*, the

European Medicines Agency and The United States Food & Drug Administration, require this to be done by assaying for serial infection using what is commonly called a “roller bottle” assay.

In this method, target cells (*e.g.*, HEK cells) are grown in culture medium. A sample of the viral vector is then added to transduce the target cells, and the cells are cultured long enough to allow transduction to complete. The target cells are then pelleted and rinsed to remove any residual viral vector in the media. The target cells are then lysed, and the lysate is added to a culture of assay cells (*e.g.*, HeLa cells). The assay cells are then grown in media for a long enough time to enable infectious virus (if any) to produce visible infection of the assay cells. Optionally, these assay cells may be again pelleted, rinsed, lysed and the lysate added to a second culture of assay cells, which are in turn grown in media. Visible infection is determined microscopically, observing the assay cells to visually determine whether they have been infected with virus. That visual inspection is an assessment of visible cellular stress; infected cells become visibly deformed and look poorly, while in the absence of infectious virus the assay cells look normal. This test is often referred to as a “roller bottle” test because the assay cells are typically cultured in roller bottles.

The roller bottle assay has been understood to be sensitive enough to detect <1 RCA in 3×10^{10} viral particles. The roller bottle test is somewhat subjective because it relies on microscopic observation of assay cells' morphology. To find a more objective assay, we tested various alternative approaches. In comparing alternative assays to the industry-standard roller bottle assay, we surprisingly found that, contrary to the teachings of the art, the roller bottle

assay is not sensitive enough to detect <1 RCA in 3×10^{10} viral particles. To the contrary, we have found that the roller bottle assay is only able to detect ≥ 75 RCA in 3×10^{10} viral particles.

We thus have invested the time to develop an alternative approach using digital PCR. This can be faster than the prior art approach, provides more objective data and, surprisingly, is an order of magnitude more sensitive, able to detect, for example, as few as seven (7) RCA in 3×10^{10} viral particles.

Brief Summary:

This disclosure describes an assay to detect replication competent virus ("RCV"), for example replication competent adenovirus ("RCA"), with digital polymerase chain reaction (dPCR). Preferably, one may use droplet digital PCR (ddPCR) because the equipment is readily available. Our assay contains multiple amplification cycles of RCA in cell culture and detection of the amplified RCA by ddPCR method.

Brief Description of the Figures:

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with drawing(s) will be provided by the Office upon request and payment of the necessary fees. Figure 1 provides a flow chart overview of our assay.

Figure 2 is a color photograph or reprint of the QuantaSoft software user interface.

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

Detailed Description:

Our assay is outlined in Figure 1. In Figure 1, suspension-cultured HeLa cells are used to amplify possible RCA. The cells are seeded into 500 ml shaker flasks at a density of 7.5×10^7 cells/flask. To each flasks is added 3×10^{10} virus particles (vp) of test sample (TS). After three days of incubation (+37 °C, 5% CO₂, 122 rpm), the cells are collected and lysed with three freeze-thaw cycles. The lysate is cleared by centrifugation.

The lysate is then added to 125 ml shaker flasks of fresh assay cells (2×10^7 cells/flask). These first assay culture flasks are handled the same way as the target cell culture.

The lysate from the first assay culture is then added to a second assay culture (2×10^7 cells/flask. After three days of incubation, the second assay culture cells are collected and lysed. The lysate is cleared by centrifugation and stored in ultra-low temperature freezer. Multiple RCA amplification cycles are performed to minimize interfering effects of therapeutic protein (e.g., transgene in the viral vector coding for, for example, interferon, which would impede growth of interferon-sensitive assay cells) and to maximize RCA yield.

RCA in the lysate is detected by digital polymerase chain reaction (dPCR) method. We prefer to use ddPCR, and thus discuss it below, but other dPCR methods may be used as well.

The lysate is pre-treated with proteinase K to release viral DNA encapsulated inside the viral particles.

The pre-treated lysate is used as a sample in ddPCR analysis with PCR primers and a probe (e.g., a TaqMan probe) specific for a part of the viral genome

101 region which has been deleted from the virus (to render it replication-incompetent)
102 For example, we have used this method to assay an adenovirus from which the
103 E1 region has been deleted. The E1 region is essential for the adenovirus
104 replication and is therefore deleted from the genome of various adenoviral gene
105 therapy vectors, but is present in the wild-type (infective) genome.

106 In our ddPCR analysis, we prepared a mixture including supermix,
107 primers and probe, and then pipetted it on triplicate wells on a 96-well plate.
108 The lysate sample (from above) is added on each of the wells. We then used an
109 automated droplet generator to generate thousands of small droplets. The
110 sample DNA randomly divides between the droplets. The DNA inside the
111 droplets is amplified by PCR. The droplets are read using a reader which counts
112 positive and negative droplets. The result is calculated using Poisson
113 distribution and given as copies/ μ l.

114 We have used this protocol for replication-deficient adenovirus gene
115 therapy vector, but conceptually one may use it for any other replication-
116 deficient virus which has a genome amenable to PCR analysis. Similarly, we
117 have tested this system on viral vector containing a transgene for vascular
118 endothelial growth factor D ("VEGF-D"), but one may use it with vector having
119 another transgene.

120 As reference standard (RS) for the assay, we used Phase I clinical-grade
121 material at a density of 1.77×10^{11} vp/ml. RS is treated similarly to test sample
122 (TS). We prepared duplicate RS flasks. The results of TS are reported against
123 the reference standard.

Amplification is controlled by a negative control (NC). NC is prepared by “mock-infecting” the cells with cell culture medium. NC is prepared as a single flask because we know the expected result.

We used a positive control (PC) prepared by infecting the target cells with 100 vp of wild-type (replication-competent) adenovirus reference material (“ARM”), ATCC catalog No. VR-1516. We use PC for trending purposes only, preparing PC in duplicate.

ddPCR is controlled by a no-template control (NTC). In the NTC, the sample is replaced by the same cell culture medium which was used to dilute the samples, and a positive control of purified ARM DNA (in which cell-free DNA which was extracted from ARM material is used as the sample). We used an original concentration of ARM DNA of 322.1 ng/μl. The ARM DNA was then diluted to 10 ng/μl and aliquoted to aliquots of 12 μl/tube. The aliquots were stored at -20 °C. Each aliquot should be thawed no more than five (5) times to minimize freeze-thaw damage to the DNA. We prefer to memorialize or record each thawing on the thawed tube, and discard and aliquot after the 5th thawing.

The assay uses HeLa QCWCB2 cells cultured in DMEM supplemented with 10% FBS / Pen/Strep / L-glutamine. The cells are cultured in suspension shaker flasks of different sizes in e.g., a CO₂ incubator equipped with a shaker platform or a New Brunswick S41i™ incubator shaker.

We have found the process is most efficient if performed by two operators on the days of first infection, second infection and third infection. One operator seeds HeLa suspension cells for the assay (7 to 15 flasks for infection and 1 to 5 flasks for further culturing). Another operator prepares viral dilutions for first

infection or lyses infected cells during second and third infection. Only one operator is required for harvest and for dPCR analysis.

Cell Culture

Cell culturing is performed according to aseptic technique. HeLa QCWCB2 cells were cultured in suspension. The number of cell flasks required for RCA assay depends on the number of TS to be analyzed. One flask is reserved for NC, two flasks for RS and two flasks for PC. Each TS will be analyzed as duplicates. Maximum of five TSs can be analyzed in one assay (in total 15 flasks).

In order to have the required number of flasks, the culture needs to be adequately scaled up. Table I presents our recommended minimal number of flasks to be seeded to start the assay with different number of test samples (TSs). Shaker flasks of 250 ml and 500 ml are interchangeable so that one 500 ml flask corresponds to two 250 ml flasks. Note that the scaling up needs to be started early enough to obtain required amount of cells: for assays with 4 – 5 TS, this means roughly two weeks before starting the assay, and for assays with 1 – 3 TS the preceding week.

Table I Scaling up HeLa suspension culture for RCA assay								
			Number of flasks					
Week	Day	Task	For 5 TS	For 4 TS	For 3 TS	For 2 TS	For 1 TS	Size of flasks
1	Thu/Fri	Cell culturing	2	2	1	1	1	250 ml
2	Mon/Tue	Cell culturing	4	4	3	3	2	250 ml
2	Fri	Cell culturing	9	8	7	5	4	500 ml
3	Tue	First infection	15	13	11	9	7	500 ml
			5	4	4	3	3	250 ml
3	Fri	Second infection	15	13	11	9	7	125 ml
			4	4	3	3	2	250 ml
4	Mon	Third infection	15	13	11	9	7	125 ml
			1	1	1	1	1	250 ml

The recommended minimal number of flasks to be seeded to start the assay with different number of test samples (TS) are presented. Scaling up should be started 1 – 2 weeks before the assay. Week days are exemplary and can be adjusted as needed. The flasks needed for the assay are indicated; additionally, multiple flasks need to be seeded for further culturing at the same time.

Before seeding the cells for RCA assay, the growth of the culture is monitored and the cells are counted. We prefer to use the following system suitability criteria (SSC) for cells: cell viability $\geq 80\%$, and RSD% (Relative Standard Deviation) of cell counting, $\leq 20\%$.

When seeding the cells to be infected in RCA assay, we prefer to use seeding parameters as presented in Table II.

Table II Cell seeding parameters for RCA assay			
RCA assay step	Size of flask	cells/flask	Volume/flask (ml)
First infection	500 ml	1.00E+08	100 ¹⁾
Second infection	125 ml	2.00E+07	40
Third infection	125 ml	2.00E+07	40
¹⁾ 100 ml of medium will be added 90 ± 10 min after the infection			

180

181

182

183

184

185

186

187

188 First Infection / Transduction:

189

190

191

192

193

194

195

We prefer the first infection be performed in 500 ml flasks with 1×10^8 cells/flask. This cell amount is seeded in 100 ml of medium. After the infection, 100 ml of medium is added. The final cell density in the flask is 5×10^5 cells/ml. Test article dose per one flask is 3×10^{10} vp. The dose per cell is 300 vp/cell. The second and the third infection are performed in 125 ml flasks with 2×10^7 cells/flask in 40 ml of medium. The cell density is 5×10^5 cells/ml. The seeded cells are infected on the same day.

For the first infection (or “transduction” where a recombinant virus with a transgene is used), viral vector dilutions are prepared in cold medium (taken from refrigerator). Throughout the protocol cross-contamination is avoided. The virus samples are handled in the following order as applicable: 1) NC, 2) TSs, 3) RS, 4) PC.

a) Mark virus titers (vp/ml).

b) Calculate virus dilutions.

- c) Synchronize the work with the operator seeding the cells so that the virus dilutions and the cells to be infected are ready approximately at the same time.
- d) Thaw RS, ARM and TSs in refrigerator and keep them cold until immediately before use.
- e) Take the needed volume of cold medium into 50 ml tube. The needed volume is as follows: approximately 7.0 ml for preliminary dilutions of PC, approximately 8.5 ml for final dilutions for NC, RS and PC flasks, and approximately 4.5 ml for each TS. (As a result approximately 20 ml is needed for one TS and approximately 40 ml for five TS).
- f) Prepare preliminary dilutions of PC (ARM) according to Table III. We have found that ARM has to be heavily diluted by a dilution series in order to achieve desired doses in appropriate volumes. Each dilution needs to be thoroughly mixed before using it to prepare the next one.

Table III Dilution series of ARM

Dilution	Dilution Factor	Dilution to be used	Volume of dilution (μl)	Volume of medium (μl)	Total volume (μl)	Final conc. (vp/ml)
Dil1	100	Neat	10	990	1 000	5.8×10^9
Dil2	100	Dil1	10	990	1 000	5.8×10^7
Dil3	100	Dil2	10	990	1 000	5.8×10^5
Dil4	100	Dil3	10	990	1 000	5.8×10^3
PC	58	Dil4	43	2457	2 500	100
Neat ARM (5.8×10^{11} vp/ml) will be used to prepare Dilution 1. The following Dilutions 2 – 4 and the final PC will be prepared by using the preceding ones.						

g) Prepare final dilutions. Pipet medium first to all the tubes, then test articles, RS and PC only as the last one. Note that two replicate dilution are prepared for RS, PC and each TS. Use the dilutions within 90 minutes from preparation.

h) Infect 500 ml shaker flasks with 1×10^8 cells in 100 ml of medium with medium (NC) and with final dilutions. Use all of the dilution (2 ml) for infection.

i) Approximately 90 minutes (± 10 min) after the infection, add 100 ml of fresh pre-warmed medium into the flasks with infected cells.

j) Incubate the flasks with the infected cells for three days ($+37^\circ\text{C}$, 5 % CO_2 , 122 rpm).

Note that the assay can be paused after the first infection. Follow the steps a) – h) above. Transfer the supernatants into clean 15 ml sterile centrifuge tubes. Freeze the tubes quickly with liquid nitrogen and store in ultra-low freezer for maximum of two months. On the day of second infection, thaw the frozen supernatants in refrigerator and use all of the supernatants for infecting fresh cells.

Second Infection:

For the second infection, medium (taken from refrigerator) is needed for re-suspending the cells. The virus samples are handled in the following order as applicable: 1) NC, 2) TSs, 3) RS, 4) PC.

a) Synchronize the work with the operator seeding the cells so that the supernatant for infection and the cells to be infected are ready approximately at the same time.

b) Fill liquid nitrogen container up with liquid nitrogen.

- c) Transfer infected cell suspension (200 ml) from each of the shaker
flasks into 50 ml sterile tubes (4 tubes/sample).
- d) Centrifuge the cells down 1 000 x g for 10 min at +4 °C.
- e) Remove supernatants.
- f) Re-suspend cell pellets of one sample with 5 ml of fresh cold medium.
Add the medium in one tube, re-suspend the pellet by pipetting,
transfer the suspension to the second tube of the same sample, re-
suspend again and repeat until all four tubes of the sample are
handled.
- g) Transfer the suspension into 15 ml sterile centrifuge tubes (1
tube/sample).
- h) Lyse the cells by 3 cycles of freezing with liquid nitrogen
(approximately 5 min) and thawing in water bath at +37 °C
(approximately 10 min). The tubes are placed in a metallic cage which
can be immersed in liquid nitrogen and in warm water in a row. After
each freezing, check that the tubes are intact before placing them in
warm water. After each thawing, confirm again that there is no cracks
in the tubes and vortex the tubes at low speed. The work can be
paused during one of the freezing steps. Keep the samples frozen
(liquid nitrogen/-80 °C) until you are ready to continue.
- i) Centrifuge the lysed cells 2 000 x g for 20 min at +4 °C to get rid of the
cell debris. Retain the supernatants.

j) If HeLa suspension cells to be infected are not ready, the supernatants are transferred into clean tubes and kept cold (refrigerator) until the cells are ready.

k) Infect 125 ml shaker flasks with 2×10^7 cells in 40 ml with the supernatant. Use all of the supernatants (approximately 5 ml) for infection.

l) Incubate the flasks with the infected cells for three days (+37 °C, 5 % CO₂, 122 rpm).

The assay can be paused after the second infection. Follow the steps a) – h) above. Transfer the supernatants into clean 15 ml sterile centrifuge tubes. Freeze the tubes quickly with liquid nitrogen and store in ultra-low freezer for maximum of two months. On the day of third infection, thaw the frozen supernatants in refrigerator and use all of the supernatants for infecting fresh cells.

Third Infection:

For the third infection, cold medium (taken from refrigerator) is used for re-suspending the cells. The virus samples are handled in the following order as applicable: 1) NC, 2) TSs, 3) RS, 4) PC.

a) Synchronize the work with the operator seeding the cells so that the supernatant for infection and the cells to be infected are ready approximately at the same time.

b) Fill liquid nitrogen container up with liquid nitrogen.

c) Transfer infected cell suspension (40 ml) from each of the shaker flasks into 50 ml sterile tubes (1 tube/sample).

d) Centrifuge the cells down 1 000 x g for 10 min at +4 °C.

- 285 e) Remove supernatants.
- 286 f) Re-suspend cell pellets of one sample with 2 ml of fresh cold medium. If
287 the pellets are very dense and hard to re-suspend, the re-suspending
288 volume can be increased.
- 289 g) Transfer the suspension into 15 ml sterile centrifuge tubes (1
290 tube/sample).
- 291 h) Lyse the cells by 3 cycles of freezing with liquid nitrogen
292 (approximately 5 min) and thawing in water bath at +37 °C
293 (approximately 10 min). The tubes are placed in a metallic cage which
294 can be immersed in liquid nitrogen and in warm water in a row. After
295 each freezing, check that the tubes are intact before placing them in
296 warm water. After each thawing, confirm again that there is no cracks
297 in the tubes and vortex the tubes at low speed. The work can be paused
298 during one of the freezing steps. Keep the samples frozen (liquid
299 nitrogen/-80 °C) until you are ready to continue.
- 300 i) Centrifuge the lysed cells 2 000 x g for 20 min at +4 °C to get rid of the
301 cell debris. Keep the supernatant.
- 302 j) If HeLa suspension cells to be infected are not ready, the supernatants
303 are transferred into clean tubes and kept cold (refrigerator) until the
304 cells are ready.
- 305 k) Infect 125 ml shaker flasks with 2×10^7 cells in 40 ml with the
306 supernatant. Use all of the supernatants (approximately 2 ml) for
307 infection.

- l) Incubate the flasks with the infected cells for three days (+37 °C, 5 % CO₂, 122 rpm).

Harvest:

To harvest,. sample labels may be printed according to Table IV. Each flask of infected cells needs four labels: two with aliquot size of 110 µl and two with <1000 µl.

Table IV Example labels for harvest aliquots

	Example 1	Example 2
RCA-yy-nnn	RCA-19-001	RCA-19-002
DD-MMM-YYYY/Initials	21-FEB-2019/HP	17-JAN-2019/MJK
Sample name	NC	TS1_1
Aliquot size	110 µl	<1000 µl

Cold medium (taken from refrigerator) is needed for re-suspending the cells. The virus samples are handled in the following order as applicable: 1) NC, 2) TSs, 3) RS, 4) PC.

- a) Fill liquid nitrogen container up with liquid nitrogen.
- b) Label 1 ml cryotubes for harvest aliquots.
- c) Transfer infected cell suspension (40 ml) from each of the shaker flasks into 50 ml sterile tubes (1 tube/sample).
- d) Centrifuge the cells down 1 000 x g for 10 min at +4 °C.
- e) Remove supernatants.
- f) Re-suspend cell pellets of one sample with 2 ml of fresh cold medium. If the pellets are very dense and hard to re-suspend, the re-suspending volume can be increased.
- g) Transfer the suspension into 15 ml sterile centrifuge tubes (1 tube/sample).

h) Lyse the cells by 3 cycles of freezing with liquid nitrogen (approximately 5 min) and thawing in water bath at +37 °C (approximately 10 min). The tubes are placed in a metallic cage which can be immersed in liquid nitrogen and in warm water in a row. After each freezing, check that the tubes are intact before placing them in warm water. After each thawing, confirm again that there is no cracks in the tubes and vortex the tubes at low speed. The work may be paused during one of the freezing steps. Keep the samples frozen (liquid nitrogen/-80 °C) until you are ready to continue.

i) Centrifuge the lysed cells 2 000 x g for 20 min at +4 °C to get rid of the cell debris. Keep the supernatants.

j) Transfer the supernatants into new clean tubes and mix.

k) Aliquot the supernatant of each sample into pre-labeled 1 ml cryotubes: 2 x 110 µl; 2 x <1000 µl.

l) Freeze the aliquots quickly with liquid nitrogen and store in freezer until analyzed.

Digital PCR Analysis:

DNA work should be performed under nuclease free conditions. Sterile nuclease-free solutions and plastic ware must be used. Gloves must be worn at all times when handling DNA samples. DNA-ExitusPlus™ may be used to remove possible DNA residues after work. After cleaning the laminar flow hood ("LFH") dedicated for DNA samples, the LFH may be inactivated by UV illumination overnight.

To pre-treat the harvest samples, thaw harvest samples at room temperature for maximum of one hour. Pipette the samples (100 µl/well) on a 96

well plate: NC to well A4. RS_1, RS_2, PC_1, PC_2, TS1_1 and TS1_2 to column 1 on wells B1 – G1. Rest of the TSs to column 6 on wells A6 – H6. Add Proteinase K (1 µl/well) to used wells. Seal the plate tightly with optical adhesive cover. Vortex gently and spin shortly. Run the plate with Applied Biosystems 7500 Real-Time PCR system with the latest version of SDS template document “Prot K”. The run program is as follows: Incubate for 60 min at +50 °C. Incubate for 20 min at +95 °C. Cool the samples down to +4 °C. If not continuing straight to sample dilutions, store the plate in refrigerator.

For sample dilution, samples need to be diluted to fall on dynamic range of ddPCR analysis. Dilutions of 1:1000 and 1:10000 are used in the analysis. If none of these dilutions is acceptable, higher or lower dilutions can be tested. Pipette cell culture medium (90 µl/well) on wells B2 – G5 of the 96 well plate with pre-treated harvest samples. Pipette cell culture medium (90 µl/well) on wells A7 – H10. Pipette cell culture medium (90 µl/well) on well H4. This well will be used to prepare NTC for ddPCR analysis. Mix pre-treated samples on columns 1 and 6 thoroughly by pipetting. Prepare dilution series from column 1 all the way to column 5 and from column 6 all the way to column 10. Pipette 10 µl from column 1 to column 2 and mix the prepared dilution thoroughly by pipetting. Pipette 10 µl from column 2 to column 3 and mix. Continue until column 5 is ready and mixed. Repeat the same for columns 6 – 10. If not continuing straight to ddPCR analysis store the plate in refrigerator.

Preparing the ddPCR Plate:

To prepare a ddPCR plate, a fresh 1 pg/µl dilution of ARM DNA is prepared from 10 ng/µl aliquot for each RCA assay aiming to product release. See Table V for dilution series of ARM DNA.

Table V Dilution series to prepare ARM DNA to be used as PC in ddPCR analysis

Name	Dilution factor	Dilution to be used	Volume of dilution (μl)	Volume of water (μl)	Total volume (μl)	Final concentration
Dil1	10	Neat	2	18	20	1 ng/μl
Dil2	10	Dil1	5	45	50	0.1 ng/μl
Dil3	10	Dil2	10	90	100	10 pg/μl
ARM DNA	10	Dil3	10	90	100	1 pg/μl

Each dilution needs to be thoroughly mixed by pipetting before using it to prepare the next one. The dilutions are prepared in DNA LFH. The last dilution named ARM DNA (1 pg/ μl) is used in ddPCR run. Volume to be used is 5 μl i.e., 5 pg of ARM DNA is used in each reaction.

Fresh dilutions of Forward primer, Reverse primer and TaqMan probe for RCA are prepared for each RCA assay aiming to product release. In our experiments, we used an E1-deleted adenovirus, and thus as used as Forward primer for RCA, 5'- AAC CAG TTG CCG TGA GAG TTG -3'; as Reverse primer for RCA, 5'- CTC GTT AAG CAA GTC CTC GAT ACA -3' and as TaqMan probe for RCA, 5'- TGG GCG TCG CCA GGC TGT G -3'.

The reagents are thawed at room temperature, mixed and spun down (e.g. with centrifuge/vortexer). See Table VI for dilution instructions.

Table VI Dilutions of Forward primer for RCA, Reverse primer for RCA and TaqMan probe for RCA						
Reagent	Dilution factor	Original concentration	Volume of reagent (μl)	Volume of water (μl)	Total volume (μl)	Final concentration
Forward	16.7	100000 nM	19	297	316	6000 nM
Reverse	16.7	100000 nM	19	297	316	6000 nM
Probe	40	100000 nM	8	312	320	2500 nM

The dilutions are prepared in Master mix laminar. Final concentrations of the primers (6000 nM) and the probe (2500 nM) are used in ddPCR run. Volume of 2.5 μl of each reagent is added to reaction mixture with total volume of 25 μl. The concentrations in reaction mixture are 600 nM for the primers and 250 nM for the probe. For analytical development, in-process samples and characterization purposes, earlier prepared dilutions stored at -20 °C can be used. Master mix is prepared in LFH dedicated for master mix preparation. The sample are added on the plate in DNA LFH. Separate materials, pipettes and centrifuge/vortexers are used for master mix and DNA work. Calculate the needed well amount and the needed total volume of master mix. Thaw the ddPCR supermix for probes at room temperature and vortex at high speed when thawed. Mix the diluted Forward primer, Reverse primer and TaqMan probe for RCA and spin the reagents down. We found that a centrifuge/vortexer can be conveniently used for mixing and spinning. Prepare the master mix for ddPCR as per Table VII, and vortex at high speed.

Table VII Components of master mix for ddPCR.		
Reagent	Volume / reaction (μl)	Volume required for 113 reactions (μl)
ddPCR supermix for probes	12.5	1412.5
Forward primer for RCA	2.5	282.5
Reverse primer for RCA	2.5	282.5
TaqMan probe for RCA	2.5	282.5
Total volume	20	2260
The example is for maximum number of test samples. Modify the volumes as needed.		

413

414

Pipette the master mix (20 μl/well) on wells of a 96 well plate.

415 Optionally, the master mix can be poured on a reagent reservoir and a

416 multichannel pipette can be used to pipette the mixture on the plates. Add

417 ddPCR Buffer Control Kit (BC, 25 μl/well) on wells H4 – H6 and on wells not

418 needed for samples. For maximum number of test samples, note that all wells of

419 each column need to be filled. ddPCR Buffer Control Kit (“BC”) is used on wells

420 not needed for samples. We prefer to use wells with *e.g.*, 1:1000 and 1:10000

421 dilutions.

422 We prefer to mix the 96 well plate with pre-treated samples and dilutions

423 by vortexing and spin the samples down. Add samples (5 μl/well) to the ddPCR

424 plate with the master mix (20 μl/well). After usage, store the sample plate in

425 refrigerator. The samples can be used to repeat the ddPCR analysis.

426 For control, mix ARM DNA dilution by pipetting and add (5 μl/well) to

427 the ddPCR plate (wells A4, A5 and A6).

Seal the plate with Heatfoil using a plate sealer at +180 °C for 5 seconds.

Vortex the plate briefly and spin the sample mixtures down. Continue to droplet generation and PCR run.

Droplet Generation, PCR Reading and Droplet Reading:

We prefer to perform automated droplet generation with an AutoDG™ device. To do so, we seal the plate with droplets with Heatfoil, using a plate sealer at +180 °C for 5 seconds. Then continue with PCR run. We prefer to run the plate with C1000™ Touch Thermal Cycler with and PCR conditions as provided in Table VIII.

Table VIII PCR conditions for RCA assay

Step	Used conditions			
	Temperature	Time	Ramp	Cycles
Initial denaturation	+95 °C	10 min	2 °C/s	1
Denaturation	+94 °C	30 s	2 °C/s	40
Annealing/extension	+60 °C	1 min	2 °C/s	
Enzyme deactivation	+98 °C	10 min	2 °C/s	1
Hold	+4 °C	∞	N/A	1
Temperature of the lid is set to +105 °C. Sample volume is 40 µl because the AutoDG device combines 20 µl of reaction mixture with 20 µl of AutoDG oil.				

After the PCR run the droplets are stable. The plate can be stored in refrigerator overnight. Read the droplets with Droplet Reader with the latest version of QuantaSoft template “RCA ddPCR”. QuantaSoft software automatically creates a folder for the run and saves the run as QuantaSoft plate document. After the run, set threshold manually at 2000 for all the wells as follows: Click “Analyze” button on the left-hand menu; Select all the wells from plate layout on the right-hand upper corner; Select “1D amplitude” display; On the bottom of the left-hand menu, activate a button with yellow markings (multi-well tool). This allows you

to set the threshold for all the wells simultaneously. Set the threshold by entering 2000 to Set Threshold box (press Enter). See Figure 2 for visualization of threshold setting and a more detailed description of the software user interface. Close the QuantaSoft software and click “Yes” as the software prompts to select “Save plate information?”. Copy the created folder to server and ensure that it has the assay run number as folder name.

ddPCR run data is automatically analyzed by QuantaSoft software. Fulfillment of SSC is evaluated and the results are read with the software.

Data Analysis:

In ddPCR technique sample DNA is randomly divided between thousands of droplets. Accuracy of the analysis is the better the more droplets are present. The QX200 ddPCR system is capable to generate and read over 20 000 droplets per well. To secure the desired accuracy a criterion of ≥ 8000 accepted droplets is set for each analysed well. However the assay does not fail although individual wells fails this criterion. The failing wells are omitted from the further analysis. Each sample is analyzed on triplicate wells in ddPCR analysis. The result of the sample can be read if at least two of the triplicate wells have ≥ 8000 accepted droplets. To check the number of accepted droplets proceed as follows: Open the plate document (with threshold 2000) saved on the server. Click “Analyze” button on the left-hand menu. Select all the wells from plate layout on the right-hand upper corner. Select “Events” display. Tick “total” box on the right. For clarity other boxes (pos/neg) should not be ticked. Check from the values on the histogram that each well has ≥ 8000 accepted droplets.

System suitability criteria for NC, NTC and ARM DNA are that at least two of the triplicate wells have ≥ 8000 accepted droplets. Check if the criteria passes. If the criteria fails, the ddPCR analysis needs to be repeated. When considering further SSC, take only the wells with ≥ 8000 accepted droplets into account.

In ddPCR analysis, a sample having ≥ 5 positive droplets is considered negative. Samples having 6 – 34 positive droplets cannot be considered negative but might be contaminated or represent very low amount of the target DNA. Samples having ≥ 35 positive droplets are considered clearly positive. the number of positive and negative droplets on each well is checked by the procedure described above a) – e) but ticking pos or neg boxes instead of total.

Assay SSC for NC, NTC and ARM DNA are: Any of the accepted wells of NC sample has no more than 5 positive droplets, or Any of the accepted wells of NTC has no more than 5 positive droplets, or At least two of the triplicate wells of ARM DNA show ≥ 35 positive droplets.

If these SSC fail, we prefer that the ddPCR be repeated. If NC still fails, we suggest that the whole RCA assay starting from the first infection be repeated. If the reason for the failure is NTC or ARM DNA, the RCA amplification might have been successful but there is something wrong with the ddPCR analysis. In the case of repeated failure of NTC or ARM DNA, the reason for the failure needs to be investigated.

In order to read the result of a certain sample, the sample should have both positive and negative droplets. The accuracy of the analysis is compromised if the amount of negative droplets is low. The well should show > 100 negative

droplets. Otherwise the well is considered as “saturated” and the result of that well cannot be read.

Dynamic range of ddPCR analysis is narrow. RS and TSs are analyzed as two dilutions: 1:1000 and 1:10000. At least one of the dilutions needs to be within the range. Criteria for acceptable RS dilution are that at least two of the triplicate wells show ≥ 8000 accepted droplets, > 100 negative droplets (the well is not saturated) and ≥ 35 positive droplets (the well shows positive result).

Evaluate assay SSC with the acceptable dilution(s). Assay SSC for RS is: Both RS_1 and RS_2 show positive result (≥ 35 positive droplets) at acceptable dilution(s) on acceptable wells. SSC passes if both RS_1 and RS_2 have at least one acceptable dilution. The reason for SSC failure can be inappropriate dilution. The used dilutions may be too low (the wells saturate) or too high (negative results). In this case, the ddPCR can be repeated with adjusted dilutions. Dilutions 1:10 and/or 1:100 from the pre-treatment plate can be used as appropriate or a further dilution from 1:10000 can be prepared. Consult a specialist to decide how to proceed. If one of replicative flasks (RS_1 or RS_2) still shows negative result while the other is within the dynamic range, the whole RCA assay starting from first infection needs to be repeated.

Criteria for acceptable TS dilution is that at least two of the triplicate wells show ≥ 8000 accepted droplets and > 100 negative droplets (the well is not saturated). Evaluate sample SSC with the acceptable dilution(s). Note that TS are not required to pass the criteria of ≥ 35 positive droplets as TS may be free of RCA.

Sample SSC is: Both TSX_1 and TSX_2 have at least one acceptable dilution. If the sample fails SSC, its result cannot be reported and the sample needs to be re-analysed. However the results of the other samples can be read and reported. The reason for SSC failure can be inappropriate dilution. The used dilutions may be too low (the wells saturate). In this case, the ddPCR can be repeated with adjusted dilutions. Further dilution from 1:10000 can be prepared.

Results of RCA Assay:

The result of ddPCR analysis is given as copies/ μ l. QuantaSoft software reports this value for each well on Results table on the left-hand upper corner. The value is 0 if there is no positive droplets on the well and the value is 1000000 (saturated) if there is no negative droplets on the well. To calculate the results of RS and TS, record the concentration (copies/ μ l) reported in Results table of QuantaSoft software for each well. Record only the concentrations for the accepted wells and dilutions; otherwise mark N/A. Then calculate the adjusted concentration (copies/ μ l) by multiplying the reported concentration by dilution factor. Then calculate the average (copies/ μ l) of the adjusted concentrations. Record it with as whole number without decimals. Note that if one of the replicative flask of a certain TS (TSX_1 or TSX_2) gives a negative result with both dilutions, the average is calculated from the positive flask. For RS, calculate the RS range as average \pm 20 %: the lower end of the range is 0.8 x Average, and the higher end of the range is 1.2 x Average. Results of TS are compared to this RS range. For each TS, compare average to RS range. If the average is below RS range, the results is "LESS RCA than in RS". If the average

is within RS range, the result is "EQUAL AMOUNT of RCA as in RS". If the average is above RS range, the result is "MORE RCA than in RS".

If one of the replicative flask of a certain TS (TSX_1 or TSX_2) gives a negative result with both dilutions and the other gives clearly positive result, the average (copies/ μ l) is based on the positive flask. If the comparison to RS range gives a result of "MORE RCA than in RS", the ddPCR analysis needs to be repeated. If the result is still the same, the whole RCA assay starting from the first infection needs to be repeated.

Assay results may be trended to an Excel™ file. We prefer that the following parameters are trended:

- RCA assay running number
- Assay SSC PASS/FAIL
- Reason for possible SSC failure
- Result (copies/ μ l) of ARM DNA
- Acceptable dilutions for RS and PC
- Average (copies/ μ l) for RS and PC (Note that average for PC is calculated in trending excel only.)

Based on our disclosure, the artisan may easily make variations to it. for example, while we have in fact developed our improved assay using recombinant adenovirus bearing a transgene for vascular endothelial growth factor D, our assay can also identify replication-competent contaminant virus in vector with other transgenes (e.g., p53, interferon etc).

"Infection" refers to a virus replicating in a target cell to form progeny. In contrast, "transfection" refers to delivery via a viral vector of foreign DNA or

565 RNA into a target cell. Transfection does not require the virus replicate in the
566 target cell.

567 Similarly, while we in fact tested our assay on a viral vector intended to
568 not replicate at all in a human patient, our assay can as readily be used on viral
569 vector intended to replicate conditionally, e.g., to replicate only in cancerous
570 human cells but not in normal human cells. We thus use the phrase “unable to
571 replicate in normal human cells” in the appended legal claims to indicate this.

572 Similarly, while our experiments have been done on adenovirus, our
573 method is as readily useful for other types of gene therapy viral vectors.

574 We thus intend the legal coverage of our patent to be defined not by our
575 specific laboratory work described above, but by our appended legal claims and
576 their permissible equivalents.

We claim:

1. A method for identifying virus able to replicate in normal human cells in a sample comprising viral gene therapy vector unable to replicate in normal human cells, the method comprising:

- a. Obtaining a sample comprising viral gene therapy vector unable to replicate in normal human cells, the viral vector comprising a transgene and a viral genome which has been genetically modified from a wild-type viral genome by having a modification or deletion of a region of the wild-type viral genome essential for replication of the virus in a normal human cell, whereby the resulting viral gene therapy vector is intended to be unable to replicate in normal human cells, and then
- b. Mixing the sample with live target cells which can be transduced by the viral gene therapy vector to make a transduction mixture, and then
- c. Maintaining the transduction mixture for a time and under conditions adequate to enable the viral gene therapy vector to transduce the target cells, and then
- d. Separating the target cells from any residual sample, and then
- e. Lysing the target cells to release their intracellular contents, and then
- f. Mixing the intracellular contents of the lysed target cells with live assay cells which can be infected by the virus to make an infection mixture, and then
- g. Maintaining the infection mixture for a time and under conditions adequate to enable the virus (if any) to infect the assay cells, and then
- h. Lysing the assay cells to release their intracellular contents, and then

i. Isolating nucleic acid from the assay cells' intracellular contents, and then

j. Evaluating the isolated nucleic acid by digital PCR, using a probe which hybridizes to said region of the viral genome essential for viral replication which has been modified or deleted,

thereby measuring in the sample the approximate quantity of virus able to replicate in normal human cells.

2. The method of claim 1, where the virus is adenovirus and wherein the probe comprises a DNA probe having a sequence comprising a sequence selected from: SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3.

3. The method of claim 1, wherein the method detects as few as 25 virus able to replicate in normal human cells per 3×10^{10} viral gene therapy vector particles unable to replicate in normal human cells.

4. The method of claim 3, wherein the method detects as few as 7 virus able to replicate in normal human cells per 3×10^{10} viral gene therapy vector particles unable to replicate in normal human cells.

5. The method of claim 1, wherein the transgene expresses a polypeptide selected from the group consisting of: interferon and p53.

6. A pharmaceutical finished dosage form comprising pharmaceutically-acceptable excipient and a viral gene therapy vector unable to replicate in normal human cells and comprising a transgene, the dosage form having not more than about 25 virus particles able to replicate in normal human cells per 3×10^{10} viral particles unable to replicate in normal human cells.

7. The pharmaceutical finished dosage form of claim 6, having not more than about 7 virus particles able to replicate in normal human cells per 3×10^{10} viral particles unable to replicate in normal human cells.

8. The pharmaceutical finished dosage form of claim 6, wherein the virus is an adenovirus.

9. The pharmaceutical finished dosage form of claim 6, wherein the transgene expresses a polypeptide selected from the group consisting of: interferon and p53.

10. The pharmaceutical finished dosage form of claim 9, wherein the transgene expresses interferon.

11. The pharmaceutical finished dosage form of claim 10, having not more than about 7 virus particles able to replicate in normal human cells per 3×10^{10} viral particles unable to replicate in normal human cells.

12. The pharmaceutical finished dosage form of claim 9, wherein the transgene expresses p53.

13. The pharmaceutical finished dosage form of claim 12, having not more than about 7 virus particles able to replicate in normal human cells per 3×10^{10} viral particles unable to replicate in normal human cells.




FIGURE 1





FIGURE 2



HeLa QCWCB2 cells
Suspension culture
Shaking 122 rpm/min, 37°C, 5% CO ₂

1 st infection	HeLa (7.5×10^7 cells) + Test article (3×10^{10} vp) ↓ 3 days → lysates
2 nd infection	Fresh HeLa (2.0×10^7 cells) + viral lysate ↓ 3 days → lysates
3 rd infection	Fresh HeLa (2.0×10^7 cells) + viral lysate ↓ 3 days → samples

Pre-treatment with proteinase K
Automated droplet generating
PCR run with specific primers and TaqMan probe
Droplet reading

FIGURE 1